OpenAlex
PricingAboutJobs
Log inGet started
Work

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial

HTML

Year: 2012
Type: article
Study design: Clinical Trial
Source: Neurology
DOI: 10.1212/wnl.0b013e31824e8ee7
Authors: A.J. Coles, E. Fox, A. Vladic, S.K. Gazda, V. Brinar, K.W. Selmaj, A. Skoromets, I. Stolyarov, A. Bass, H. Sullivan, D.H. Margolin, S.L. Lake, S. Moran, J. Palmer, M.S. Smith, D.A.S. Compston
Institutions: University Hospital Centre Zagreb, University of Cambridge, Central Texas Neurology Consultants, Medical University of Lodz, Addenbrooke's Hospital, Russian Academy of Sciences, Trinity Health
Language: English

Topic: Multiple Sclerosis Research Studies
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Keywords: alemtuzumab, interferon beta-1a, relapsing-remitting multiple sclerosis, long-term efficacy, disability progression, relapse rate, treatment safety, serious infections, thyroid dysfunction, idiopathic thrombocytopenic purpura, long-term follow-up, immunomodulatory therapy, B-cell depletion
SDG: Good health and well-being

Open Access status: closed

Funder: National Institute for Health and Care Research
Award: NIHR Senior Investigator Award
OpenAlex ID: W2107422246
FWCI: 24.32
Cites: 14
Cited by: 269
Related to: 9
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms